[Heparins]

Area of Science:

• Pharmacology
• Hematology
• Thrombosis Research

Context:

• Unfractionated heparin (UH) and low-molecular-weight heparins (LMWH) are crucial antithrombotic agents.
• LMWH has largely replaced UH for venous thromboembolism (VTE) and arterial occlusions due to improved safety and convenience.
• Heparin-induced thrombocytopenia (HIT) risk is significantly lower with LMWH.

Purpose:

• To compare the efficacy and monitoring of unfractionated heparin (UH) and low-molecular-weight heparins (LMWH).
• To review the current indications and monitoring strategies for UH and LMWH in anticoagulation therapy.
• To highlight the advantages of LMWH over UH in most clinical scenarios.

Summary:

• LMWH offers a more favorable risk-benefit profile than UH, with a tenfold lower risk of HIT.
• UH is reserved for complex cases requiring rapid reversal of anticoagulation.
• Monitoring of UH involves aPTT, TT, or anti-Xa assays, while LMWH monitoring is typically only needed in specific populations (pregnant women, children, renal impairment).
• Therapeutic ranges for UH infusion and subcutaneous LMWH are established, guiding dose adjustments.

Impact:

• Provides guidance on the appropriate use and monitoring of UH and LMWH.
• Supports the transition towards LMWH for routine anticoagulation, improving patient safety.
• Informs clinical practice regarding the selection of anticoagulants based on patient-specific factors and risk profiles.